摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-hydroxymethyl-7-mercapto-5-methyl-s-triazolo[1,5-a]pyrimidine | 121171-04-8

中文名称
——
中文别名
——
英文名称
2-hydroxymethyl-7-mercapto-5-methyl-s-triazolo[1,5-a]pyrimidine
英文别名
7-mercapto-5-methyl-s-triazolo[1.5-a]pyrimidine-2-methanol
2-hydroxymethyl-7-mercapto-5-methyl-s-triazolo[1,5-a]pyrimidine化学式
CAS
121171-04-8
化学式
C7H8N4OS
mdl
——
分子量
196.233
InChiKey
FJIAEEYQCYHCRS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 密度:
    1.65±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.21
  • 重原子数:
    13.0
  • 可旋转键数:
    1.0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.29
  • 拓扑面积:
    63.31
  • 氢给体数:
    2.0
  • 氢受体数:
    6.0

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    "Triazolo-pyrimidine intermediates"
    摘要:
    公开了一种β-内酰胺化合物,其由以下通式(I)表示: ##STR1## 其中R1表示酰基;M表示氢原子,或可在人体内易水解的可消除保护基团;B表示由通式(b)表示的基团: ##STR2## 其中至少一个R2、R3和R9表示由以下通式表示的基团:-A-OR4,其中R4表示氢或低级烷基;A表示具有1至6个碳原子的直链或支链亚烷基;剩余的基团或基团各自独立地为氢原子;氰基;可被卤素原子取代的低级烷基;可被低级烷基取代的氨基甲酰基;环烷基;或可被易在人体内水解的可消除保护基团取代的羧基,当R9为-A-OR4时,R2和R3可以相互结合形成具有3至4个碳原子的亚烷基;Z表示氮原子或由以下通式表示的基团:C-R10,其中R10表示氢原子、羧基或可被羟基或低级烷氧基取代的低级烷基,或其药学上可接受的盐,以及制备该化合物的方法、用于合成该化合物的中间体和含有该化合物的用于细菌感染疾病治疗的药物组合物。
    公开号:
    US04956462A1
  • 作为产物:
    参考文献:
    名称:
    Cephalosporins with sulfur-containing oxyimino side chain
    摘要:
    公式为##STR1##的抗菌化合物,其中R是单核碳环芳基,含有氧或硫原子或亚胺或较低烷基亚胺基作为杂环(非碳)环成员的5-成员芳香杂环基,可选地,一个或两个氮原子,或者含有一个到三个氮原子作为杂环环成员的6-成员芳香杂环基;R.sup.1是氢或在头孢菌素化学中可用的3-取代基;A是较低烷基或可选地取代有羧基、氨基甲酰基、较低烷基氨基甲酰基或二(较低烷基)氨基甲酰基的C.sub.3-7-环烷基;Q是较低烷基或可选地取代有羧基、氨基甲酰基、较低烷基氨基甲酰基或二(较低烷基)氨基甲酰基的C.sub.3-7-环烷基,或者是基团--NR.sup.2--或--NR.sup.2 NR.sup.3--;R.sup.2和R.sup.3独立地是氢或较低烷基;p和m为零或1,n为零、1或2;R.sup.4是氢、较低烷酰基或三(较低烷基)硅基;两个R.sup.4基团一起代表二苯甲亚甲基;R.sup.5是氢、较低烷基、羟基、较低烷氧基、卤素、硝基、--OCOR.sup.7、--OCOOR.sup.71、--N(R.sup.7).sub.2、--NHCOR.sup.7、--NHCOOR.sup.71、--COR.sup.7、--SR.sup.7、--SOR.sup.7、--SO.sub.2 R.sup.7、--SO.sub.3 H、--COOR.sup.7或--CON(R.sup.7).sub.2;R.sup.6是氢、较低烷基或卤素,R.sup.7是氢或较低烷基;R.sup.71是较低烷基,两个--OR.sup.4基团通过相邻碳原子连接到苯环上,以及这些化合物的容易水解的酯和药用可接受盐以及公式I的化合物和其酯和盐的水合物。
    公开号:
    US05036064A1
点击查看最新优质反应信息

文献信息

  • Intermediates for synthesis of cephalosporin compounds
    申请人:Sankei Pharmaceutical Co., Ltd.
    公开号:US04958019A1
    公开(公告)日:1990-09-18
    There are disclosed a .beta.-lactam compound represented by the formula (I): ##STR1## wherein R.sub.1 represents an acyl group; M represents a hydrogen atom, a protective group or an eliminatable group which is easily hydrolyzable in a human body; B represents a group represented by the formula (b): ##STR2## where at least one of R.sub.2, R.sub.3 and R.sub.9 represent a group represented by the formula: --A--OR.sub.4 where R.sub.4 represents a hydrogen or a lower alkyl group; and A represents a straight or branced alkylene group having 1 to 6 carbon atoms; and a remaining group or groups are each independently a hydrogen atom; a cyano group; a lower alkyl group which may be substituted by a halogen atom; a carbamoyl group which may be substituted by a lower alkyl group; a cycloalkyl group; or a carboxyl group which may be substituted by a protective group or an eliminatable group which is easily hydrolyzable in a human body, and also when R.sub.9 is --A--OR.sub.4, R.sub.2 and R.sub.3 may be combined with each other to form an alkylene group having 3 to 4 carbon atoms; and Z represents a nitrogen atom or a group represented by the formula: C--R.sub.10 where R.sub.10 represents a hydrogen atom, a carboxyl group or a lower alkyl group which may be substituted by a hydroxy group or a lower alkoxy group, or its pharmaceutically acceptable salt, and a process for preparing the same, an intermediate for synthesis of the same and a medicinal composition for bacterially infectious disease therapy containing the same.
    公开了一种β-内酰胺化合物,其化学式为(I): ##STR1## 其中R.sub.1代表酰基;M代表氢原子,保护基或易解的可消除基,在人体中易解;B代表化学式(b)所代表的基团:##STR2## 其中R.sub.2、R.sub.3和R.sub.9中至少有一个代表化学式--A--OR.sub.4所代表的基团,其中R.sub.4代表氢原子或较低的烷基基团;A代表具有1到6个碳原子的直链或支链烷基基团;其余的基团各自独立地代表氢原子;基;可能被卤原子取代的较低烷基基团;可能被较低烷基基团取代的基甲酰基基团;环烷基团;或可能被保护基或在人体中易解的可消除基团取代的羧基基团;当R.sub.9为--A--OR.sub.4时,R.sub.2和R.sub.3可以结合形成具有3到4个碳原子的烷基基团;Z代表氮原子或化学式C--R.sub.10所代表的基团,其中R.sub.10代表氢原子、羧基或可能被羟基或较低的烷氧基取代的较低烷基基团,或其药学上可接受的盐,以及制备它的过程,用于治疗细菌感染疾病的药物组合物。
  • Cephalosporin derivatives
    申请人:Sankei Pharmaceutical Co., Ltd.
    公开号:US04987129A1
    公开(公告)日:1991-01-22
    There are disclosed a .beta.-lactam compound represented by the formula (I): ##STR1## wherein R.sub.1 represents an acyl group; M represents a hydrogen atom, a protective group or an eliminatable group which is easily hydrolyzable in a human body; B represents a group represented by the formula (b): ##STR2## where at least one of R.sub.2, R.sub.3 and R.sub.9 represent a group represented by the formula: --A--OR.sub.4 where R.sub.4 represents a hydrogen or a lower alkyl group; and A represents a straight or branched alkylene group having 1 to 6 carbon atoms; and a remaining group or groups are each independently a hydrogen atom; a cyano group; a lower alkyl group which may be substituted by a halogen atom; a carbamoyl group which may be substituted by a lower alkyl group; a cycloalkyl group; or a carboxyl group which may be substituted by a protective group or an eliminatable group which is easily hydrolyzable in a human body, and also when R.sub.9 is --A--OR.sub.4, and R.sub.3 may be combined with each other to form an alkylene group having 3 to 4 carbon atoms; and Z represents a nitrogen atom or a group represented by the formula: C--R.sub.10 where R.sub.10 represents a hydrogen atom, a carboxyl group or a lower alkyl group which may be substituted by a hydroxy group or a lower alkoxy group, or its pharmaceutically acceptable salt, and a process for preparing the same, an intermediate for synthesis of the same and a medicinal composition for bacterially infectious disease therapy containing the same.
    公开了一种β-内酰胺化合物,其表示为式(I):##STR1##其中,R.sub.1表示酰基;M表示氢原子、保护基或易于在人体内解的可消除基;B表示由式(b)表示的基团:##STR2##其中,R.sub.2、R.sub.3和R.sub.9中的至少一个表示由式--A--OR.sub.4表示的基团,其中R.sub.4表示氢或较低的烷基基团;A表示具有1到6个碳原子的直链或支链烷基基团;剩余的基团分别独立地表示氢原子、基、可以被卤素原子取代的较低烷基基团、可以被较低烷基基团取代的基甲酰基团、环烷基团或可以被易于在人体内解的保护基或可消除基取代的羧基团,当R.sub.9是--A--OR.sub.4时,R.sub.3可以相互结合形成具有3到4个碳原子的烷基基团;Z表示氮原子或由式C--R.sub.10表示的基团,其中R.sub.10表示氢原子、羧基或可以被羟基或较低的烷氧基取代的较低烷基基团,或其药学上可接受的盐,以及制备其的过程、合成其的中间体和用于治疗细菌感染疾病的药物组合物。
  • Cephalosphorins with sulfur-containing oxyimino side chain
    申请人:Hoffmann-La Roche Inc.
    公开号:US05073550A1
    公开(公告)日:1991-12-17
    Antibacterial compounds of the formula ##STR1## wherein R is a mononuclear carbocyclic aromatic group, a 5-membered aromatic heterocyclic group which contains as the hetero (non-carbon) ring member(s) an oxygen or sulphur atom or an imino or lower alkylimino group and, optionally, one or two nitrogen atoms, or a 6-membered aromatic heterocyclic group which contains one to three nitrogen atoms as the hetero ring member(s); R.sup.1 is hydrogen or a 3-substituent which is usable in cephalosporin chemistry; A is lower alkylene or C.sub.3-7 cycloalkylene which is optionally substituted with carboxy, carbamoyl, lower alkylcarbamoyl or di-(lower alkyl)carbamoyl; Q is lower alkylene or C.sub.3-7 cycloalkylene which is optionally substituted with carboxy, carbamoyl, lower alkylcarbamoyl or di(lower alkyl)carbamoyl, or the group --NR.sup.2 -- or --NR.sup.2 NR.sup.3 --; R.sup.2 and R.sup.3 are independently hydrogen or lower alkyl; p and m are the zero or 1, n is zero, 1 or 2; R.sup.4 is hydrogen, lower alkanoyl or tri(lower alkyl)silyl; two R.sup.4 groups together represent diphenylmethylene; R.sup.5 is hydrogen, lower alkyl, hydroxy, lower alkoxy, halogen, nitro, --OCOR.sup.7, --OCOOR.sup.71, --N(R.sup.7).sub.2, --NHCOR.sup.7, --NHCOOR.sup.71, --COR.sup.7, --SR.sup.7, --SOR.sup.7, --SO.sub.2 R.sup.7, --SO.sub.3 H, --COOR.sup.7 or --CON(R.sup.7).sub.2 R.sup.6 is hydrogen, lower alkyl or halogen, R.sup.7 is hydrogen or lower alkyl; R.sup.71 is lower alkyl, and the two --OR.sup.4 groups are attached to the phenyl ring via adjacent carbon atoms, as well as readily hydrolyzable esters and pharmaceutically acceptable salts of these compounds and hydrates of compounds of formula I and of their esters and salts.
    化合物的抗菌化合物公式为##STR1##其中R是单核芳香环烃基,5-成员芳香杂环基,其包含氧或原子或亚胺或低烷基亚胺基作为杂(非碳)环成员,可选地含有一个或两个氮原子,或者是含有一个到三个氮原子作为杂环成员的6-成员芳香杂环基; R.sup.1是氢或可在头孢菌素化学中使用的3-取代基; A是低烷基或C.sub.3-7环烷基,可选地取代羧基,基甲酰基,低烷基基甲酰基或二(低烷基)基甲酰基; Q是低烷基或C.sub.3-7环烷基,可选地取代羧基,基甲酰基,低烷基基甲酰基或二(低烷基)基甲酰基,或者是--NR.sup.2 --或--NR.sup.2 NR.sup.3 --基团; R.sup.2和R.sup.3独立地是氢或低烷基; p和m为零或1,n为零,1或2; R.sup.4是氢,低烷酰基或三(低烷基)基; 两个R.sup.4基团共同代表二苯基甲烯基; R.sup.5是氢,低烷基,羟基,低烷氧基,卤素,硝基,--OCOR.sup.7,--OCOOR.sup.71,--N(R.sup.7).sub.2,--NHCOR.sup.7,--NHCOOR.sup.71,--COR.sup.7,--SR.sup.7,--SOR.sup.7,--SO.sub.2 R.sup.7,--SO.sub.3 H,--COOR.sup.7或--CON(R.sup.7).sub.2 R.sup.6是氢,低烷基或卤素,R.sup.7是氢或低烷基; R.sup.71是低烷基,两个--OR.sup.4基团通过相邻的碳原子连接到苯环上,以及这些化合物的易解酯和药学上可接受的盐以及公式I和其酯和盐的化合物和合物。
  • Intermediates for cephalosporins with sulfur containing oxyimino side
    申请人:Hoffmann-La Roche Inc.
    公开号:US05319140A1
    公开(公告)日:1994-06-07
    Antibacterial compounds of the formula ##STR1## wherein R is a mononuclear carbocyclic aromatic group, a 5-membered aromatic heterocyclic group which contains as the hereto (non-carbon) ring member(s) an oxygen or sulphur atom or an imino or lower alkylimino group and, optionally, one or two nitrogen atoms, or a 6-membered aromatic heterocyclic group which contains one to three nitrogen atoms as the hereto ring member(s); R.sup.1 is hydrogen or a 3-substituent which is usable in cephalosporin chemistry; A is lower alkylene or C.sub.3-7 -cycloalkylene which is optionally substituted with carboxy, carbamoyl, lower alkylcarbamoyl or di(lower alkyl)carbamoyl; Q is lower alkylene or C.sub.3-7 -cycloalkylene which is optionally substituted with carboxy, carbamoyl, lower alkylcarbamoyl or di(lower alkyl)carbamoyl or the group --NR.sup.2 -- or --NR.sup.2 NR.sup.3 --; R.sup.2 and R.sup.3 are independently hydrogen or lower alkyl; p and m are the zero or 1, n is zero, 1 or 2; R.sup.4 is hydrogen, lower alkanoyl or tri(lower alkyl)silyl; two R.sup.4 groups together represent diphenylmethylene; R.sup.5 is hydrogen, lower alkyl, hydroxy, lower alkoxy, halogen, nitro, --OCOR.sup.7, --OCOOR.sup.71, --N(R.sup.7).sub.2, --NHCOR.sup.7, --NHCOOR.sup.71, --COR.sup.7, --SR.sup.7, --SOR.sup.7, --SO.sub.2 R.sup.7, --SO.sub.3 H, --COOR.sup.7 or --CON(R.sup.7).sub.2 ; R.sup.6 is hydrogen, lower alkyl or halogen, R.sup.7 is hydrogen or lower alkyl; R.sup.71 is lower alkyl, and the two --OR.sup.4 groups are attached to the phenyl ring via adjacent carbon atoms, as well as readily hydrolyzable esters and pharmaceutically acceptable salts of these compounds and hydrates of compounds of formula I and of their esters and salts.
    公式为 ##STR1## 的抗菌化合物,其中 R 是单核芳香烃基,5-成员芳香杂环基,其中含有氧或原子或亚胺或低烷基亚胺基作为其(非碳)环成员,可选地含有一或两个氮原子,或6-成员芳香杂环基,其中含有一到三个氮原子作为其环成员; R.sup.1 是氢或可用于头孢菌素化学中的3-取代基; A 是低烷基或C.sub.3-7-环戊烷基,可选地取代为羧基,基甲酰基,低烷基基甲酰基或二(低烷基)基甲酰基; Q 是低烷基或C.sub.3-7-环戊烷基,可选地取代为羧基,基甲酰基,低烷基基甲酰基或二(低烷基)基甲酰基或基团--NR.sup.2--或--NR.sup.2NR.sup.3--; R.sup.2 和 R.sup.3 分别是氢或低烷基; p 和 m 为零或1,n 为零、1或2; R.sup.4 是氢、低烷酰基或三(低烷基)基; 两个 R.sup.4 组成二苯甲基; R.sup.5 是氢、低烷基、羟基、低烷氧基、卤素、硝基、--OCOR.sup.7、--OCOOR.sup.71、--N(R.sup.7).sub.2、--NHCOR.sup.7、--NHCOOR.sup.71、--COR.sup.7、--SR.sup.7、--SOR.sup.7、--SO.sub.2R.sup.7、--SO.sub.3H、--COOR.sup.7或--CON(R.sup.7).sub.2; R.sup.6 是氢、低烷基或卤素,R.sup.7 是氢或低烷基; R.sup.71 是低烷基,两个--OR.sup.4基通过相邻碳原子连接到苯环上,以及这些化合物的容易解的酯和药学上可接受的盐以及公式I和其酯和盐的化合物和合物。
  • Intermediates for cephalosporins with sulfur-containing oxyimino side
    申请人:Hoffmann-La Roche, Inc.
    公开号:US05138066A1
    公开(公告)日:1992-08-11
    Antibacterial compounds of the formula ##STR1## wherein R is a mononuclear carbocyclic aromatic group, a 5-membered aromatic heterocyclic group which contains as the hetero (non-carbon) ring member(s) an oxygen or sulphur atom or an imino or lower alkylimino group and, optionally, one or two nitrogen atoms, or a 6-membered aromatic heterocyclic group which contains one to three nitrogen atoms as the hetero ring member(s); R.sup.1 is hydrogen or a 3-substituent which is usable in cephalosporin chemistry; A is lower alkylene or C.sub.3-7 -cycloalkylene which is optionally substituted with carboxy, carbamoyl, lower alkylcarbamoyl or di(lower alkyl)carbamoyl; Q is lower alkylene or C.sub.3-7 -cycloalkylene which is optionally substituted with carboxy, carbamoyl, lower alkylcarbamoyl or di(lower alkyl)carbamoyl, or the group --NR.sup.2 -- or --NR.sup.2 NR.sup.3 --; R.sup.2 and R.sup.3 are independently hydrogen or lower alkyl; p and m are the zero or 1, n is zero, 1 or 2; R.sup.4 is hydrogen, lower alkanoyl or tri(lower alkyl)silyl; two R.sup.4 groups together represent diphenylmethylene; R.sup.5 is hydrogen, lower alkyl, hydroxy, lower alkoxy, halogen, nitro, --OCOR.sup.7, --OCOOR.sup.71, --N(R.sup.7).sub.2, --NHCOR.sup.7, --NHCOOR.sup.71, --COR.sup.7, --SR.sup.7, --SOR.sup.7, --SO.sub.2 R.sup.7, --SO.sub.3 H, --COOR.sup.7 or --CON(R.sup.7).sub.2 ; R.sup.6 is hydrogen, lower alkyl or halogen, R.sup.7 is hydrogen or lower alkyl; R.sup.71 is lower alkyl, and the two --OR.sup.4 groups are attached to the phenyl ring via adjacent carbon atoms, as well as readily hydrolyzable esters and pharmaceutically acceptable salts of these compounds and hydrates of compounds of formula I and of their esters and salts.
    化合物的抗菌成分的公式为##STR1##其中R是单核芳香碳环基团,5-成员芳香杂环基团,其中包含杂(非碳)环成员的氧或原子或亚胺或低烷基亚胺基团,并且可选地包含一个或两个氮原子,或者是包含1至3个氮原子的6-成员芳香杂环基团;R.sup.1是氢或可用于头孢菌素化学的3-取代基;A是低烷基或C.sub.3-7-环烷基,可选地取代羧基,基甲酰基,低烷基基甲酰基或二(低烷基)基甲酰基;Q是低烷基或C.sub.3-7-环烷基,可选地取代羧基,基甲酰基,低烷基基甲酰基或二(低烷基)基甲酰基,或者是--NR.sup.2--或--NR.sup.2NR.sup.3--基团;R.sup.2和R.sup.3独立地是氢或低烷基;p和m为0或1,n为0、1或2;R.sup.4是氢,低烷酰基或三(低烷基)基;两个R.sup.4基团一起代表二苯甲基;R.sup.5是氢,低烷基,羟基,低烷氧基,卤素,硝基,--OCOR.sup.7,--OCOOR.sup.71,--N(R.sup.7).sub.2,--NHCOR.sup.7,--NHCOOR.sup.71,--COR.sup.7,--SR.sup.7,--SOR.sup.7,--SO.sub.2R.sup.7,--SO.sub.3H,--COOR.sup.7或--CON(R.sup.7).sub.2;R.sup.6是氢,低烷基或卤素,R.sup.7是氢或低烷基;R.sup.71是低烷基,两个--OR.sup.4基团通过相邻碳原子连接到苯环上,以及这些化合物的容易解的酯和药学上可接受的盐以及公式I和它们的酯和盐的化合物和合物。
查看更多

同类化合物

阿扎次黄嘌呤 钠2-氨基-6-甲基-[1,2,4]三唑并[1,5-a]嘧啶-5-醇 苯酚,4-[2-[[7-氨基-2-(2-呋喃基)[1,2,4]三唑并[1,5-a][1,3,5]三嗪-5-基]氨基]乙氧基]- 替格雷洛-d7 替格瑞洛羟基杂质 替格瑞洛杂质R1788033-05-5摩科品牌提供图谱 替格瑞洛杂质K 替格瑞洛杂质J 替格瑞洛杂质H 替格瑞洛杂质F 替格瑞洛杂质85 替格瑞洛杂质27 替格瑞洛杂质 替格瑞洛杂质 替格瑞洛中间体1脱保护杂质 替格瑞洛 曲匹地尔 异亚丙基替卡格雷 布美地尔 唑嘧菌胺 唑嘧磺草胺 吡唑并[1,5-a]嘧啶-7(4H)-酮,2-甲基-6-硝基-,盐钠 去羟基乙氧基替格雷洛 去羟基乙氧基-2,3-O-(二甲基亚甲基)替格雷洛 化合物 T15173 v-三唑并[4,5-d]嘧啶,(3H),3-环戊基-7-偏基硫代- [[[3-(4,7-二氢-7-氧代-1H-1,2,3-三唑并[4,5-d]嘧啶-5-基)-4-丙氧基苯基]氨基]亚甲基]丙二酸二乙酯 [1,2,4]噻唑并[1,5-c]嘧啶-5(6h)-酮 [1,2,4]三氮唑并[1,5-A]嘧啶-2-胺 [1,2,4]三唑并[3,4-f]嘧啶 [1,2,4]三唑并[1,5-a]嘧啶-7-酚,5-壬基- [1,2,4]三唑并[1,5-a]嘧啶-7(1H)-酮,2-甲基-6-硝基-,盐钠 [1,2,4]三唑并[1,5-A]嘧啶-2-羧酸甲酯 [1,2,4]三唑并[1,5-A]嘧啶-2-羧酸 [1,2,4]三唑[1,5,A]嘧啶-7-氨基 [(1R,3S)-3-(5-氨基-7-氯-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基)环戊基]甲醇 [(1R,3S)-3-(5,7-二氨基-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基)环戊基]甲醇 N-甲基-1H-1,2,3-三唑并[4,5-d]嘧啶-7-胺 N-(4'-氟丁酰苯)-4-(4-氯苯基)吡啶正离子 N-(2,6-二氯苯基)-5,7-二甲基[1,2,4]三唑并[1,5-a]嘧啶-2-磺酰胺 N-(2,6-二氯-3-甲苯基)-5,7-二甲氧基-[1,2,4]三唑[1,5-a]嘧啶-2-磺酰胺 N-(2,6-二氯-3-甲基苯基)-5,7-二氯-1,2,4-三唑并[1,5-a]吡啶-2-磺酰胺 N-(1,5,6,7-四氢-3,6-二甲基-5,7-二氧代-1,2,4-三唑并[4,3-c]嘧啶-8-基)-乙酰胺 EED抑制剂(EEDINHIBITOR-1) 9H-7,8-二氢-(1,2,3)三唑并(4',5'-4,5)嘧啶并(6,1-b)(1,3)噻嗪-5(3H)-酮 9-乙基-2,4,7,8,9-五氮杂双环[4.3.0]壬-1,3,5,7-四烯-3,5-二胺 8-甲氧基-3-甲基-[1,2,4]三唑并[4,3-C]嘧啶 8-甲基-1,3,7,9-四氮杂双环[4.3.0]壬-2,4,6,8-四烯 8-溴-[1,2,4]三唑并[4,3-c]嘧啶 8-溴-5-(甲硫基)[1,2,4]三唑并[4,3-c]嘧啶